Novartis (NVS) Receives FDA Breakthrough Therapy Designation for Ianalumab, Shares Rise 1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: stocktwits
- FDA Breakthrough Designation: Novartis's Ianalumab receives Breakthrough Therapy designation from the FDA, indicating a significant potential in treating Sjögren’s disease, which may expedite the approval process and enhance market competitiveness.
- Clinical Data Submission Plans: Novartis aims to submit data from multiple trials of Ianalumab to health authorities in early 2026, and if approved, it could become the first targeted therapy for Sjögren’s disease, addressing an unmet medical need.
- Widespread Impact of Sjögren’s Disease: This chronic autoimmune disorder affects the entire body, with over 90% of patients experiencing dry eyes and mouth, and the success of Ianalumab could significantly improve patients' quality of life, highlighting its social value.
- Positive Stock Reaction: Following the FDA designation announcement, Novartis shares rose by 1%, reflecting market optimism regarding its future treatment potential, which may attract more investor interest.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 129.00 USD with a low forecast of 118.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 143.150
Low
118.00
Averages
129.00
High
140.00
Current: 143.150
Low
118.00
Averages
129.00
High
140.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
